



CHANDAN HEALTHCARE LIMITED

Reg. Off. Add: Biotech Park, Sector-G, Jankipuram, Kursi Road, Lucknow-226021

CIN: L85110UP2003PLC193493

TELNO.: -8069366666 Email: secretarial@chandan.co.in

www.chandandiagnostic.com

Date: February 16, 2026

To,

The Listing Department

National Stock Exchange of India Ltd.

Exchange Plaza, Plot no. C/1, G Block,
Bandra- Kurla Complex, Bandra (East),
Mumbai - 400 051

Symbol: CHANDAN

ISIN: INE0B2N01016

Subject: Investor Presentation for the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2025.

Dear Sir/Madam,

Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we are enclosing herewith a copy of the Investor Presentation on the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2025.

The same shall also be made available on the Company's website at www.chandandiagnostic.com.

You are requested to take the above information on record.

Yours faithfully,

For Chandan Healthcare Limited

Rajeev Kumar Nain

Company Secretary & Compliance Officer

Encloses: As above



Chandan Healthcare Limited
Investor Presentation Q3 & 9M FY26



Disclaimer



This presentation and the accompanying slides (the Presentation), which have been prepared by **Chandan Healthcare (Chandan, The Company)** solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment what so ever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantee of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict.

These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company's ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company's market preferences and its exposure to market risks, as well as other risks.

The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.



Management Comments On Q3 & 9M FY26 Financial Performance



Amar Singh

Promoter, Chairman and Managing Director

We delivered a steady performance in Q3 FY26 with Total Income of ₹65.77 Cr and EBITDA of ₹12.61 Cr, reflecting healthy operating momentum and improved efficiencies. Our continued focus on network expansion, value-added testing, and operational discipline supported stable margins and consistent growth during the quarter.

During the quarter, we entered into an exclusive five-year partnership with Jeena Sikho Lifecare to provide comprehensive diagnostic services across its existing and upcoming hospitals and centres. This strategic collaboration is expected to generate meaningful recurring revenues at healthy margins over the coming years. We have already commenced the operational rollout under this partnership by setting up diagnostic facilities, and this will progressively ramp up going forward. In addition, we secured a key B2G contract during the quarter, adding business stability and ensuring steady test volumes.

We are expanding rapidly and targeting the development of around 100 labs across 17 states along with over 1,000 franchise collection points over the next three years. With a planned investment of approximately ₹100 Cr to support expansion and advanced testing capabilities including molecular diagnostics, we remain confident of strengthening our pan-India presence and driving sustainable long-term growth.







Q3 FY26 Consolidated Key Financials Highlights




Total Income



EBITDA **PAT**



EBITDA % **PAT %**




All Amount In ₹ Cr & Margins In %




9M FY26 Consolidated Key Financials Highlights




Total Income



EBITDA **PAT**



EBITDA % **PAT %**



All Amount In ₹ Cr & Margins In %



Q3 & 9M FY26 Consolidated Profit & Loss Statement



In ₹ Cr

Particulars	Q3 FY26	Q3 FY25	Y-O-Y	9M FY26	9Y FY25	Y-O-Y
Operating Income	65.01	54.64		200.81	167.47	
Other Income	0.77	0.17		2.45	0.51	
Total Income	65.77	54.82	19.99%	203.27	167.99	21.00%
Raw Material Expenses	30.05	25.73		98.94	77.20	
Employee Benefit Expenses	11.68	9.71		31.30	29.14	
Other expenses	11.44	10.30		30.44	30.91	
Total Expenditure	53.17	45.75		160.67	137.25	
EBITDA	12.61	9.06	39.08%	42.59	30.73	38.58%
EBITDA (%)	19.17%	16.54%	263 Bps	20.95%	18.30%	266 Bps
Finance Costs	1.28	1.09		4.08	3.28	
Depreciation	2.40	1.35		7.33	4.05	
PBT	8.92	6.62	34.75%	31.18	23.40	33.21%
Exceptional Items	2.23	0.00		2.23	0.00	
Tax	1.66	2.00		7.41	5.99	
PAT	5.03	4.63	8.76%	21.54	17.42	23.65%
Minority Interest	-0.49	-0.42		-1.40	-1.27	
Reported Net Profit	4.54	4.20	7.97%	20.14	16.15	24.71%
PAT (%)	6.90%	7.67%	(77) Bps	9.91%	9.61%	29 Bps
EPS (Diluted)	1.86	2.10		8.24	8.14	


Strategic Fundraise to Support Expansion and Acquisitions

Fundraise Overview

- Issuance of up to 44,50,000 fully convertible equity warrants on a preferential basis
- Issue price: ₹234 per warrant (Premium: XX)
- Total fundraise: ~₹104.13 Cr
- Participation from promoter group and strategic institutional investors
- Strategic investors include Jeena Sikho Lifecare Limited and NEGEN Undiscovered Value Fund

Utilisation of Proceeds

- **Business expansion:** ₹44.50 Cr for new diagnostic labs and centres
- **Acquisitions:** ₹50.00 Cr for centres, equipment, labs, and related assets
- **General corporate purpose:** ₹9.63 Cr



Strategic Partnership with Jeena Sikho Lifecare

Partnership Overview

- Exclusive strategic partnership with Jeena Sikho Lifecare Limited
- One of India's leading Ayurvedic healthcare providers
- Chandan Healthcare appointed as exclusive diagnostic partner
- Coverage across 23 states and 100+ cities
- Comprehensive pathology and radiology services for IPD and OPD

Operational Rollout & Scope

- Operational rollout initiated under the Jeena Sikho partnership
- First implementation at Dera Bassi, part of HiiMS Panchkula, a 100+ bed integrated hospital
- Scalable model for rollout across existing and upcoming facilities



Delhi | Prashant Vihar Diagnostic Centre



Opened a new advanced diagnostic centre

Expanded test menu to include advanced genomics testing such as whole-genome sequencing and genetic diagnostics

Multi-modality radiology including MRI, Cardiac CT, 4D Ultrasound, and Digital X-Ray

Comprehensive pathology services supporting preventive and precision healthcare



Punjab PPP Radiology Imaging Project



Awarded a long-term government PPP contract

10-year PPP project awarded by Punjab Health Systems Corporation

₹26 Cr project covering multiple government hospitals

Deployment of 3 Tesla MRI scanners and 128-slice CT technology



Bhopal Diagnostic Centre



Inaugurated and commenced operations

Full-service diagnostic centre with radiology and pathology capabilities

Equipped with MRI, Cardiac CT, 4D Ultrasound, and Digital X-Ray

Expands presence in central India and strengthens regional network



Company Overview

Redefining Diagnostics & Pharmacy in North India

Chandan Healthcare Limited is one of the leading North India-based providers of diagnostic and pharmacy services, and a key entity within the Chandan Group. The Company offers a comprehensive suite of NABL/NABH-accredited pathology and radiology solutions across Uttar Pradesh and Uttarakhand.

Its service portfolio includes a wide range of diagnostic tests such as blood tests, X-ray, ECG, ultrasound, CT scan, MRI, and other specialized investigations, ensuring reliable and high-quality care.

Chandan operates through a diverse business model spanning B2C (retail customers), B2B (institutional partnerships), and B2G (government PPP contracts) all under a company-owned model that guarantees consistent standards and operational control.

To capture rising demand across urban and semi-urban markets, Chandan is actively expanding into neighboring states including Delhi, Rajasthan, Bihar, Chhattisgarh, and Madhya Pradesh, Punjab, Maharashtra, West Bengal, Gujarat, Assam & Haryana with a strategic focus on metro hubs and Tier 2/3 cities.

The company got listed on NSE Emerge on 17th February 2025





Key Facts & Figures





Key Events & Achievements





Board Of Directors



Amar Singh

Promoter, Chairman and Managing Director

MBBS with 20+ years of experience in the healthcare industry



Asmita Singh

Promoter and Managing Director

BBA and MBA with 20+ years of marketing experience



Vinay Lamba

Non-Executive Director

Marine Engineer with 10+ years of experience in technical operations & equipment strategy



Amit Gupta

Non Executive Independent Director

B.Sc. and FCS with 20+ years of experience in corporate compliance and secretarial practice.



Brahma Nand Bhartiya

Non Executive Independent Director

B.A., M.A. with experience in labour administration; retired Assistant Labour Commissioner, UP.



Vinod Jain


Independent Director

MS (General Surgery) with fellowships from ACS and ICS.



Business Overview

Multi-Segment Model Driving Growth Across B2C, B2B & B2G



Pathology

FY25 Revenue
₹96.50 Cr
(41.94%)

Radiology

FY25 Revenue
₹ 27.80 Cr
(12.08%)

Pharmacy

FY25 Revenue
₹ 105.80 Cr
(45.98%)



Diversified revenue streams ensure stability, scalability, and reduced risk.



B2C (Retail Diagnostics)

- Walk-in services across **35+ cities & 4 states**
- **18L+ patients served** in FY25
- Strong brand recall, reliable service, affordable care

FY25 Revenue
₹135.24 Cr
(58.78%)



B2B (Institutional Clients)

- **230+ private hospitals & clinics** as partners
- Recurring, long-term relationships
- Steady revenue from integrated tie-ups

FY25 Revenue
₹42.40 Cr
(18.42%)



B2G (Government PPPs)

- Public-Private Partnerships with **state governments**
- Diagnostic services in government hospitals
- Long-term contracts ensure stable cash flow & credibility

FY25 Revenue
₹52.45 Cr
(22.80%)



Top Performing Centres Across Categories



22 Large Centres

Equipped with **MRI & advanced imaging** for comprehensive diagnostics



Top Performing Centre **Ayodhya, Rikabganj**

Revenue – ₹ 8.43 Cr
Customers Served – 85,904

29 Medium Centres

Provide **CT facilities**, but no MRI; focus on essential imaging services



Top Performing Centre **Lucknow, Indira Nagar**

Revenue – ₹ 8.98 Cr
Customers Served – 55,001

9 Small Centres

Basic healthcare & diagnostics without MRI/CT; cater to Tier-2/3 regions



Top Performing Centre **Haldwani, Nainital Road**


Revenue – ₹ 2.36 Cr
Customers Served – 25,324



Expansive Regional Footprint Across North & Central India




The complete network comprises large, medium, and small centers and 360 sample collection centers.



- Large
- Medium
- Small

State-wise Revenue



Glimpse Of Chandan's Diagnostic Centres





Enhancing Diagnostic Capabilities Through Capex



Jankipuram, Lucknow



Total capex investment: ₹24.68 Cr



Purpose: Establishment of advanced diagnostic centre



Key equipment installed:

- 384-slice CT scanner
- High-end pathology automation

3T MRI - Magnetom Lumina
(₹15.71 Cr)



Ashiyana, Lucknow



Total capex investment: ₹7.10 Cr



Purpose: Diagnostic infrastructure upgrade



Key equipment installed:

- Biomedical and imaging infrastructure enhancements

GE MRI Model Signa
HDXT 1.5T 16 Channel
(₹ 3.15 Cr)



Ayodhya, Uttar Pradesh



Total capex investment: ₹7.10 Cr



Purpose: Setup of multi-modality diagnostic centre



Key equipment installed:

- 384-slice CT scanner
- High-end pathology automation

GE MRI Model Signa HDXT 1.5T "16 Channel
(₹ 3.15 Cr)





Certified By India's Top Accrediting Bodies




Recognized For Quality Care With 5 NABH-Accredited Centres And 10 NABL-Certified Labs.


NABH Indira Nagar



NABH MKP Chowk



NABH Prayagraj



NABL Indira Nagar



NABL MKP Chowk UK



NABL Karachi Khana





Technology-Driven Healthcare at Chandan




100K+ Downloads
On Play store

- 90+ Specialties
- 24x7 Access
- One App for All Healthcare Needs

Available On
IOS

Chandan 24x7



Digital-first platform strengthening customer loyalty & operational efficiency

Unified Platform
Diagnostics, Pharmacy & Doctor Consultations

Seamless Integration
Offline + Online network, centralized medical records

Patient-Centric Features

- Lab test bookings, full-body health check-ups, home sample collection
- Appointments across **90+ medical specialties**
- Digital reports, prescriptions, purchase history
- Instant support via call centre

Chandan Family Loyalty Card

An integrated healthcare membership programme offering patients savings, convenience & holistic family coverage.



Cardholders Till Date:
40 Lakhs+



Adding Cardholders Every Month:
2 Lakhs+



Key Privileges

- Up to 70% savings on Preventive Health check ups & 10% cash back in all services
- Discounts on medicines via app & stores
- Free home sample pick-up & 2-hr delivery
- Instant reports & 24x7 support



Strategic Impact for Chandan

- Boosts customer loyalty & repeat use
- Enables cross-selling across services
- Creates recurring revenue stream
- Strengthens North India market position



Pharmacy Segment – Strong Complement To Diagnostics



Pharmacy contributes ₹ 105.8 Cr (~46% of Chandan's FY25 revenue), with a strong retail-driven model, steady institutional demand, and synergy with diagnostic services.

Service Strengths


- Widespread Retail Network:** 27 company-owned outlets across Uttar Pradesh, Uttarakhand, Madhya Pradesh, Chhattisgarh & Delhi
- Wholesale Distribution Strength:** Centralised supply chain with cold-chain compliance ensures uninterrupted medicine availability
- Integrated Healthcare Advantage:** Pharmacy complements diagnostics – boosting **customer stickiness, cross-selling & loyalty**

Consumer Category Wise Sales Contribution



In %

Product Category Wise Sales Contribution



In %

Consumer Category

Sales in ₹ Cr

Consumer Category	Sales in ₹ Cr
B2B	31.87
B2C	73.93
Total	105.80

Product Category

Sales in ₹ Cr

Product Category	Sales in ₹ Cr
Pharmaceuticals	72.78
Surgical	14.25
FMCG	5.10
Other	13.66
Total	105.80

Key Strengths Driving Sustainable Growth



Integrated Diagnostic Platform

Offers 3,500+ pathology and radiology tests under NABL/NABH-accredited infrastructure




Digital Ecosystem with Strong Adoption

100K+ downloads of Chandan 24x7 App offering e-pharmacy, doctor consultations, test bookings, and digital records



Widespread Network

Presence across 19 cities in Uttar Pradesh and all 14 districts of Uttarakhand



Tier 2/3 Market Focus

Strong presence in underserved regions with localised pricing and personalised service driving repeat business



Company-Owned Model

All diagnostic centres and labs are owned and operated by the Company, ensuring quality control and operational consistency



Scalable Growth Strategy

Entered Rajasthan and Bihar; upcoming centres in Delhi, Raipur, and Bhopal via hub-and-spoke expansion



Multi-Channel Revenue Model

Serving B2C, B2B (hospital tie-ups), and B2G (government contracts) segments

Complemented by a growing retail and wholesale pharmacy business




Experienced Leadership

Promoter-led with 20+ years of experience in healthcare, operations, and marketing





Network Expansion Plan



- Targeting a network of **100 labs across 17 states** over the next 3 years
- Expanding presence through **1,000 franchises in the next 3 years**
- Enhancing accessibility and strengthening nationwide reach

Strategic Partnership with Jeena Sikho Lifecare Limited



- Chandan Healthcare to act as the **exclusive diagnostics partner** across 23 states and 100+ cities
- Extends to upcoming Jeena Sikho facilities as their network expands
- Providing end-to-end pathology and radiology services for IPD and OPD patients

Expansion Highlights




- **New States:** Entry into Delhi, Madhya Pradesh & Chhattisgarh
- **Strengthening Presence:** Deepening network in Uttar Pradesh & NCR
- **Strategic Focus:** Addressing **diagnostic gaps** in mid-sized cities & suburban regions



Growth via Chandan Medical Centres (CMC)

- Plan to open **20+ new CMCs annually** under structured, long-term strategy
- Expanding **affordable, quality diagnostics** across underserved regions
- Delivering **integrated healthcare services closer to communities**





Industry Overview

Healthcare Demand Rising Across India's Metro & Tier-2/3 Cities



Indian Healthcare Industry Overview



Public health expenditure has steadily increased, reaching around 2.1% of GDP in FY23, up from 1.6% in FY21, with a target of increasing further toward 2.5% in coming years



The Indian healthcare market is projected to grow from approximately US\$ 367 billion by 2023 to US\$ 638 billion by 2025, representing a robust CAGR of ~22%



India is now the 4th largest medical device market globally, expected to grow rapidly



India's retail pharmacy and wellness sector will grow from US\$ 2.6 billion in 2023 to US\$ 4.1 billion by 2027 at 12% CAGR.




medical tourism sector was estimated at US\$ 7.4 billion in 2022 and is projected to cross US\$ 42 billion by 2032, making India a key destination for international patients



Source: IBEF Healthcare Feb 2025, Business Today

The Indian Healthcare Sector Is Entering Its Golden Decade.

Indian Healthcare Industry Size in (US\$ Billion)





Indian Diagnostics Sector Overview



Market Size & Growth

- Diagnostics industry expected to grow from US\$13 Billion (FY23) to US\$25 Billion (FY28) at a 14% CAGR.
- Growth driven by rising chronic diseases, ageing population, demand for preventive tests, and wider insurance coverage



Pathology Segment

- Accounts for 58% of the diagnostics market, currently valued at US\$7.5 Billion, projected to reach US\$14.4 Billion by FY28.
- India has ~1.32 lakh pathology labs, with 60%+ operating as standalone centres



Radiology Segment

- Comprises soft (X-ray, ultrasound) and advanced (CT, MRI, nuclear imaging).
- Market projected to reach US\$11 Billion by FY28, with growth led by demand in Tier 2/3 cities and advanced diagnostics.
- India has 55,000+ radiology labs, over 80% of which are standalone.



Market Structure & Opportunities

- Highly fragmented: 46% standalone, 28% private hospital labs, and 6% national chains.
- Low test prices vs developed countries indicate room for price realization and margin expansion.
- Fragmentation opens scope for consolidation and scalable models.




Healthcare Infrastructure Gap

India faces a shortfall of 3 million hospital beds, underscoring the urgent need for capacity expansion across healthcare and diagnostics.

Source: [Businessline](#)

Investor Presentation



**From Illness Detection To Preventive Care Diagnostics
Is Entering A New Era.**



Financial Overview

Consistent Growth Backed by Scale, Efficiency & Expansion

Year On Year Revenue
Growth

30.57%

Fixed Asset Turnover

2.86 Times

Interest Coverage

7.95 Times

Return on Equity

27.08%

Year on Year Profit
Growth

36.17%

Return on capital
Employed

29.34%

Debt to Equity

0.39 Times

Book Value

₹ 50.14




Key Financial Highlights




(All Amount In ₹ Cr & Margins In %)


Total Income



EBITDA **EBITDA Margin**



PAT **PAT Margin**



The Company demonstrated exceptional financial growth over FY23 to FY25. Revenue increased by 69.43%, rising from ₹137.03 Cr to 232.17 Cr, reflecting strong business expansion. EBITDA surged by 355.67%, from ₹9.52Cr to ₹43.38 Cr, driven by improved operating leverage and cost efficiencies. PAT rose by 559.82%, from ₹3.36Cr to ₹22.17Cr, indicating sharp gains in profitability and bottom-line strength.



Consolidated Profit & Loss Statement

(In ₹ Cr)



Particulars	FY23	FY24	FY25
Revenues	136.89	176.59	230.12
Other Income	0.14	1.22	2.05
Total Income	137.03	177.81	232.17
Raw Material Expenses	64.71	80.85	107.62
Employee Costs	25.49	35.42	38.86
Other Expenses	37.30	33.92	42.31
Total Expenditure	127.51	150.19	188.79
EBITDA	9.52	27.62	43.38
EBITDA Margin	6.95%	15.53%	18.69%
Finance Costs	2.42	2.75	4.58
Depreciation	2.09	3.40	6.74
PBT	5.01	21.46	32.06
Tax	1.43	5.11	8.55
Minority Interest	0.22	0.08	1.34
PAT	3.26	16.27	22.17
PAT Margin	2.46%	9.22%	9.63%



Consolidated Balance Sheet



(In ₹ Cr)

Equities & Liabilities	FY23	FY24	FY25	Assets	FY23	FY24	FY25
Equity	20.00	20.00	24.45	Non-Current Assets			
Reserves And Surplus	2.76	21.16	98.15	Fixed assets	32.56	48.49	80.45
Total Equity	22.76	41.16	122.60	Non-Current Investments	4.54	3.38	1.15
Non-Current Liabilities				Other Non Current Financial Assets	-	-	-
Long Term Borrowings	7.89	12.18	22.14	Other Non Current Assets	3.55	3.67	18.17
Other Long-Term Liabilities	-	-	-	Total Non-Current Assets	44.58	56.74	100.31
Long Term Provision	1.39	1.39	1.72	Current Assets			
Deferred Tax Liabilities	2.19	3.06	3.46	Inventories	9.87	18.24	31.37
Total Non-Current Liabilities	11.48	16.63	27.33	Trade Receivables	23.69	28.61	46.70
Current Liabilities				Cash & Bank Balance	2.04	3.90	6.21
Short Term Borrowings	13.46	23.74	26.02	Other Current Assets	3.04	2.36	16.43
Trade Payables	34.94	19.51	25.78	Other Current Financial Assets	14.91	8.22	9.60
Short Term Provisions	0.51	0.35	0.69	Total Current Assets	53.55	61.33	110.31
Other Current Liabilities	7.68	14.23	4.39	Total Assets	98.13	118.07	210.62
Total Current Liabilities	56.60	57.82	56.88				
Total Equity & Liabilities	98.13	118.07	210.62				



Consolidated Cash Flow Statement







(In ₹ Cr)

Particulars	FY23	FY24	FY25
Cash Flow from Operating Activities	4.50	1.12	-29.05
Cash Flow from Investing Activities	-6.49	-14.83	-35.75
Cash Flow from Financing Activities	2.46	15.57	67.11
Net Increase in Cash & Cash Equivalents	0.47	1.86	2.31



Key Ratios





Stock Data




As On 14-02-2026

As On 31-12-2025


NSE (CHANDAN | INEOB2N01016)

Share Price (₹)	283.85
Market Capitalization (₹ Cr)	694.07
No. of Shares Outstanding	2,44,52,064
Face Value (₹)	10.00
52-week High-Low (₹)	358.00 - 140.00

Share Holding Pattern



Share Performance From 17th February 2025 Till Date



Widespread Presence with operations across 51+ cities in 13 states, enabling deep regional penetration and first-mover advantage in underserved areas.



Integrated Diagnostics Chain offering both pathology and radiology services under one roof, driving patient stickiness and cross-selling opportunities.



Volume-Led Growth Strategy with a scalable model anchored in in-house labs, B2B referral partnerships, and low-cost collections infrastructure.



Focused Expansion in Tier 2/3 Markets, including recent entry into Delhi, Madhya Pradesh and Chhattisgarh, targeting high-growth diagnostics demand.



Experienced Promoter-Led Team with 20+ years in healthcare operations, marketing, and diagnostics strategy.



Core Diagnostics Business Drives Revenue, supported by strong unit economics, high margin radiology services, and rising test volumes.



Accredited Infrastructure including NABL-certified central labs, ensuring quality, compliance, and eligibility for government and insurance linked programmes.



Thank You



Chandan Healthcare Limited
Biotech Park, Kursi Road, Lucknow 226021 U.P.
Email: care@chandan.co.in
Phone: 08069366666
Website: www.chandandiagnostic.com



Kirin Advisors Private Limited
713-B, Lodha Supremus II, Wagle Estate,
Thane West - 400 604
E-mail: info@kirinadvisors.com
Phone: 022 4100 2455
Website: www.kirinadvisors.com